Association of Ki-67 Expression and Response of Neoadjuvant Chemotherapy in Invasive Breast Cancer Patients in Bandung
DOI:
https://doi.org/10.15850/1374Keywords:
Breast cancer, Ki-67, neoadjuvant chemotherapy, invasive breast cancer, tumour.Abstract
Objective: To analyze the association of Ki-67 expression and response of neoadjuvant chemotherapy in patients with invasive breast cancer.
Methods: A retrospective observational study on the association of Ki-67 expression and response of neoadjuvant chemotherapy in patients with invasive breast cancer was conducted. This study included twenty-five female patients with invasive breast cancer who met the inclusion criteria. Parameters analyzed were age, tumor size, and immunohistochemical expression of Ki-67. Size of the tumor at pre- and post-neoadjuvant chemotherapy were obtained in cm3 and compared between 3 groups of Ki-67 expression levels. One way ANOVA was used to perform the statistical analysis.
Results: A significant difference in changes of tumor size for Ki-67 level >20% compared to <14% and 14–20% was seen. Based on the result, neoadjuvant chemotherapy was proven to have similar effects in patients with Ki-67 expression of <14% and 14–20% but less effective in patients with Ki-67 expression of >20%.
Conclusions: Low to modest expression of Ki-67 was a better biomarker to predict the response of neoadjuvant chemotherapy in patients with invasive breast cancer compared to high expression of Ki-67. However, the cut-off value of 20% could be ideal to predict the outcome of neoadjuvant chemotherapy in patients with invasive breast cancer.
DOI: 10.15850/ijihs.v6n2.1374
References
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62(1):10–29.
World Health Organization. Cancer country profiles 2013. [cited 2016 Apr 1]. Available from: http://www.who.int/cancer/country-profiles/en/.
Lotsch J, Sipila R, Tasmuth T, Kringel D, Estlander AM, Meretoja T, et al. Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy. Breast Cancer Res Treat. 2018;72(12):399–411.
Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92(1):147–55.
Ingolf JB, Russalina M, Simona M, Julia R, Gilda S, Bohle RM, et al. Can ki-67 play a role in prediction of breast cancer patients’ response to neoadjuvant chemotherapy? Biomed Res Int [serial on the internet]. 2014 Mar [cited 2017 Aug 7];2014(1):[about 8p.]. Available from: https://www.hindawi.com/journals/bmri/2014/628217/.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–52.
Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17(1):40–6.
Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer [serial on the internet]. 2011 Nov [cited 2018 Jan 17];11(486):[about 13p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262864/.
Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A brief summary of the consensus discussion. Breast Care (Basel). 2015;10(2):124–30.
Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, et al. Evaluation of an optimal cut-off point for the ki-67 index as a prognostic factor in primary breast cancer: a retrospective study. PLoS One [serial on the internet]. 2015 Jul [cited 2017 Dec 12];10(7):[about 10p.]. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119565.
Downloads
Published
Issue
Section
License
Authors retain copyright and grant International Journal of Integrated Health Sciences right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in International Journal of Integrated Health Sciences.
